NCT06280144View on ClinicalTrials.gov

Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine

PHASE4RecruitingINTERVENTIONAL
Enrollment

6,080

Participants

Timeline

Start Date

September 22, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

October 30, 2024

Conditions
Influenza Prevention
Interventions
BIOLOGICAL

Influenza Vaccine, Live, Nasal, Freeze-dried

The titer of live attenuated influenza virus containing A (H1N1) and A (H3N2) should not be less than 6.9 lg EID50, and the titer of live attenuated influenza B virus should not be less than 6.4 lg EID50

OTHER

Sterile water for inhalation

Sterile water for inhalation

Trial Locations (1)

024000

RECRUITING

Chifeng

Sponsors
All Listed Sponsors
collaborator

Hu Bei province Center for Disease control and prevention

UNKNOWN

collaborator

The Inner Mongolia Autonomous Region Center for Disease Control and Prevention

UNKNOWN

lead

Changchun BCHT Biotechnology Co.

INDUSTRY

NCT06280144 - Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine | Biotech Hunter | Biotech Hunter